OncoMatch/Clinical Trials/NCT04519151
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Is NCT04519151 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Pembrolizumab and Lenvatinib for ovarian neoplasms.
Treatment: Pembrolizumab · Lenvatinib — This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) for the treatment of platinum sensitive recurrent ovarian cancer. Participants will receive pembrolizumab and lenvatinib.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — front-line
Have received a front-line platinum-based regimen per local standard of care or treatment guideline following the primary or interval debulking surgery with radiologically documented disease recurrence no earlier than 6 months following completion of platinum-based therapy.
Cannot have received: anti-PD-1 therapy
Exception: allowed if progression was documented over 6 months since completion of the immunotherapy maintenance treatment
Patients that received maintenance immune checkpoint inhibitors will be eligible if progression was documented over 6 months since completion of the immunotherapy maintenance treatment.
Cannot have received: lenvatinib (lenvatinib)
The participant has received prior lenvatinib.
Lab requirements
Blood counts
adequate organ function as defined by blood tests
Kidney function
adequate organ function as defined by blood tests
Liver function
adequate organ function as defined by blood tests
Have adequate organ function as defined by blood tests.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify